We use cookies for a better user experience. Read our Privacy Policy

I Agree

Post-operative Pain Therapeutics Market

Post-operative Pain Therapeutics Market (Drug Class: NSAIDs, Opioids, Local Anesthetics, Antiepileptic Drugs, Tricyclic Antidepressants, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Post-operative Pain Therapeutics Market Outlook 2031

  • The global post-operative pain therapeutics market was valued at US$ 13.0 Bn in 2021
  • The global market is projected to grow at a CAGR of 5.7% from 2022 to 2031
  • The global post-operative pain therapeutics market is anticipated to reach more than US$ 22.3 Bn by the end of 2031

Analysts’ Viewpoint on post-operative Pain Therapeutics Market Scenario

The number of surgeries requiring post-surgical pain management medications is increasing across the globe. Despite efforts to improve the provision of perioperative analgesics, the number of patients suffering from moderate to severe pain after surgery has been constant in the last decade. Opioid analgesics provide effective treatment for post-operative chronic pain; however, their usage is limited owing to side-effects such as vomiting, nausea, respiratory depression, and constipation. Hence, third-party payers and hospitals, including Medicare, Integrated Delivery Systems (IDNs), and Medicaid, are showing interest in new non-opioid pain therapies that offer effective post-operative pain relief without the adverse effects. NSAIDs and local anesthetics are effective substitutes for the relief of moderate to severe pain without the risks associated with opioids. Several pharmaceutical companies are manufacturing and marketing therapeutics in the global market to gain revenue benefits.

Post Operative Pain Therapeutics Market

Post-operative Pain Therapeutics Market Introduction

According to research conducted by the National Center for Health Statistics, a U.S. Government agency, more than 100 million surgeries are performed in the U.S. each year. Of these, at least 50 million procedures require post-surgical pain management medications. The global post-operative pain therapeutics market is projected to grow at a steady pace during the forecast period owing to advanced product development and high incidence and severity of postoperative pain. Furthermore, surge in geriatric population and introduction of promising drugs across the globe are driving the global post-operative pain therapeutics market forecast. Recently approved post-surgical pain medications such as ANJESO and ZYNRELEF have demonstrated the potential to relieve chronic pain without any side-effects. According to an article published on NCBI, in 2019, around 75% of patients who had a surgery experienced acute postoperative pain, which was often moderate to severe. Just about half of patients who have surgery report adequate postoperative pain relief. This percentage is significant, as inadequate postoperative pain control can cause adverse physiologic effects in patients in the immediate postoperative period and put them at risk of developing chronic pain from the procedure.

Request a sample to get extensive insights into the Post-operative Pain Therapeutics Market

Rise in Approval for New Drugs for Post-surgical Pain Management to Drive Global Market

Introduction of various new drugs is projected to drive the global post-operative pain therapeutics market in the next few years. New drugs are being developed with wide safety margins and favorable profiles. Advancements in non-opioid alternatives and adjuncts have gained importance in controlling post-operative pain. For instance, intravenous (IV) acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), magnesium, ketamine, dexmedetomidine, and liposomal bupivacaine are some of the drugs that have gained traction in the postoperative pain therapeutics market. Several non-opioid alternatives and adjuncts, including intravenous (IV) acetaminophen, dexmedetomidine, and liposomal bupivacaine, have gained significance in controlling post-surgical pain.

Several drug makers are coming up with novel products. In December 2021, Heron Therapeutics, Inc., a commercial-stage biotechnology firm, announced the FDA approval for ZYNRELEF (bupivacaine/meloxicam). ZYNRELEF can be used for adults for soft tissue (periarticular) instillation to produce postsurgical analgesia after small or medium open abdominal, foot, and ankle surgical procedures. In March 2022, Health Canada, a government authority responsible for national health policy, issued a notice of compliance to commercialize ZYNRELEF as post-surgical analgesia after open inguinal herniorrhaphy, bunionectomy, and other surgeries. In March 2021, Virpax Pharmaceuticals, a U.S.-based publicly-held specialty pharmaceutical company, announced it would initiate Investigational New Drug (IND) Enabling Studies for Probudur for post-surgical pain management. Thus, the launch of innovative products is expected to drive the post-operative pain therapeutics market during the forecast period.

Increase in Number of Orthopedic, Obstetric, and Gynecological Surgeries to Propel Demand for Post-surgical Pain Medications

The number of orthopedic surgeries performed globally has increased in the last few decades. Each year, around 500,000 knee replacements and more than 175,000 hip replacements are performed globally. Hence, increase in incidence of orthopedic surgeries is projected to drive the demand for medications, especially effective post-surgical pain medicines. This, in turn, is anticipated to augment the global market during the forecast period. Additionally, surge in prevalence of gynecological diseases and rise in awareness about these diseases are expected to increase the number of surgeries, which is likely to create significant opportunities in the global post-operative pain therapeutics market. Continuous innovations and developments in the field of post-operative pain therapeutics industry are also estimated to boost the post-operative pain therapeutics market size during the forecast period.

Request a custom report on Post-operative Pain Therapeutics Market

Significant Investment in Local Anesthetics for Postoperative Pain Management to Augment Local Anesthetics Segment

In terms of drug class, the global post-operative pain therapeutics market has been classified into NSAIDs, opioids, local anesthetics, antiepileptic drugs, tricyclic antidepressants, and others. The local anesthetics segment is projected to grow at a rapid pace during the forecast period. Introduction of new and effective drugs such as articaine, levobupivacaine, and ropivacaine is expected to propel the segment in the next few years. Furthermore, the local anesthetics segment is driven by the approval of new anesthetic drugs, surge in number of surgeries globally, and rise in R&D investment.

Convenient, Cost-effective, and Non-invasive Oral Medications Fueling Oral Segment

Based on route of administration, the global post-operative pain therapeutics market has been divided into oral, intravenous, intramuscular, and others. The oral segment held prominent share of the global market in 2021. Oral administration is the most convenient, safest, and simplest mode of drug administration. It is convenient for prolonged and repeated use. It can be self-administered, and is pain-free. However, the intravenous segment is projected to grow at the fastest CAGR from 2017 to 2031. Major technological innovations in the medical sector along with the emergence of effective analgesic drugs is augmenting the segment.

Major Technological Breakthroughs to Drive Online Pharmacies Segment

In terms of distribution channel, the global post-operative pain therapeutics market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The online pharmacies segment is expected to grow at a high CAGR during the forecast period. Online pharmacies (e-pharmacies) sell medicine to customers over mail or through shipping services. Online drug purchases have increased as a result of the pandemic-induced lockdowns/shutdowns. Customers have been flocking online pharmacies, demonstrating a keen interest in online medicine purchases. Businesses and customers prefer contactless delivery because of the COVID-19 induced restrictions. This has become the new normal during the pandemic and is expected to continue even after the pandemic. However, the hospital pharmacies segment is projected to account for the largest share of the global post-operative pain management therapeutics market during the forecast period. In the U.S., around 3.4 million hospital inpatients require post-operative pain medications each year.

Regional Outlook of Global Post-operative Pain Therapeutics Market

The U.S. accounted for the major share of around 40.0% of the global post-operative pain therapeutics market in 2021. The market in the country is projected to grow at a steady pace during the forecast period, primarily due to well-established healthcare infrastructure, rise in number of surgeries, favorable reimbursement policies, and significant healthcare expenditure. Additionally, presence of well-established and startup companies, such as Mallinckrodt plc, Johnson & Johnson, Cumberland Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Trevena, Inc., AcelRx Pharmaceuticals, Inc., Innocoll Holdings plc, and Heron Therapeutics, Inc., offers significant opportunities to the market in the U.S.

The European Union (EU5) held the second largest share of the global market in 2021. The post-operative pain therapeutics market in the European Union (EU5) is driven by the increase in open surgeries. Furthermore, supportive government policies for novel drug discovery are driving the post-operative pain therapeutics market in EU5.

Latin America is a larger market for post-operative pain therapeutics than Middle East & Africa. The market in Latin America is projected to grow at a faster pace than that in Middle East & Africa during the forecast period.

Analysis of Key Players in Global Post-operative Pain Therapeutics Market

The global post-operative pain therapeutics market is consolidated, with the presence of small number of leading players. Most of the companies are investing significantly in research & development activities, primarily to introduce advanced post-operative pain therapeutics. Furthermore, strategic alliances between key players to increase revenue and market share are augmenting the global market. Diversification of product portfolios and mergers & acquisitions are the key strategies adopted by the leading players. The global post-operative pain therapeutics market report includes various sections such as post-operative pain therapeutics drivers, post-operative pain therapeutics analysis, and challenges and opportunities in the post-operative pain therapeutics market. Mallinckrodt Pharmaceuticals, Pfizer, Inc., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer AG, Pacira BioSciences, Inc., and Trevena, Inc. are the prominent players operating in the global post-operative pain therapeutics market.

Key Developments in Global post-operative Pain Therapeutics Market

  • In November 2021, Antibe Therapeutics, Inc. announced it will provide further details on otenaproxesul’s development plan for acute pain indications. Otenaproxesul is an analgesic and anti-inflammatory drug being developed by Antibe Therapeutics. It is an NSAID that is structurally related to naproxen. It received approval to start phase II clinical studies in 2016 for the treatment of osteoarthritis after completing phase I trials in 2015.
  • In July 2021, Hyloris Pharmaceuticals SA, a Belgium-based innovative specialty pharmaceutical company, announced the official launch of Maxigesic IV, a novel non-opioid pain treatment, in key markets in Europe (Germany and Austria). Maxigesic IV is a non-opioid, patented, and novel treatment for post-surgical pain. It is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion.
  • In May 2017, Durect Corporation, a biopharmaceutical company committed to transforming the treatment of acute organ injury, announced a US$ 293 Mn deal with Novartis AG’s Sandoz unit, a prominent Swiss drugmaker, to develop and market Durect’s experimental non-opioid pain relief therapy, posimir, in the U.S.
  • Posimir is designed to deliver local anesthetic, bupivacaine, and provide up to three days of post-surgical pain relief. Posimir could help reduce dependence on opioid-based medications following surgery.
  • As part of the deal, Sandoz will make an upfront payment of US$ 20 Mn, and up to US$ 273 Mn in milestone payments as well as royalties on product sales

Each of these players has been profiled in the post-operative pain therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Post-operative Pain Therapeutics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 13.0 Bn

Market Forecast Value in 2031

More than US$ 22.3 Bn

Growth Rate

(CAGR)

5.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and key trend analysis.

Competition Landscape

  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • Opioids
    • NSAIDs
    • Local Anesthetics
    • Tricyclic Antidepressants
    • Antiepileptic drugs
    • Others
  • Route of Administration
    • Oral
    • Intravenous
    • Intramuscular
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others

Regions Covered

  • U.S.
  • European Union (EU5)
  • Asia Pacific
  • Latin America
  • Rest of the World (RoW)

Countries Covered

  • U.S.
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • China
  • Japan
  • South Korea
  • Singapore
  • Brazil
  • Argentina
  • Chile

Companies Profiled

  • Mallinckrodt Pharmaceuticals
  • Pfizer, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Camurus AB
  • Bayer AG
  • Pacira BioSciences, Inc.
  • Trevena, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global post-operative pain therapeutics market in 2021?

The global post-operative pain therapeutics market was valued at US$ 13.0 Bn in 2021

How big will be the global post-operative pain therapeutics market in 2031?

The global post-operative pain therapeutics market is projected to reach more than US$ 22.3 Bn by 2031

What was the CAGR of the global post-operative pain therapeutics market from 2017 to 2021?

The global post-operative pain therapeutics market contracted at a CAGR of 3.1% from 2017 to 2021

What will be the CAGR of the global post-operative pain therapeutics market during the forecast period (2022–2031)?

The global post-operative pain therapeutics market is anticipated to grow at a CAGR of 5.7% from 2022 to 2031

Which are the prominent trends that affect market growth?

Introduction of promising drugs and rise in orthopedic, obstetric, and gynecological surgeries are the key factors driving the global post-operative pain therapeutics market

What is the market share of the leading segment of the global post-operative pain therapeutics market?

The opioids segment held over 65% share of the global post-operative pain therapeutics market in 2021

Who are the prominent players in the global post-operative pain therapeutics market?

Mallinckrodt Pharmaceuticals, Pfizer, Inc., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer AG, Pacira BioSciences, Inc., and Trevena, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Post-operative Pain Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

5. Key Insights

    5.1. No. of Surgical Procedure Volume, (Orthopedic Surgery, General Surgery, Plastic Surgery, Gynecological Surgery, Ophthalmic Surgery etc.), 2020-2021

        5.1.1. North America (U.S. and Canada)

        5.1.2. European Union (Germany, U.K. France, Italy and Spain)

        5.1.3. Asia Pacific (Japan, China, India, Singapore and Korea)

        5.1.4. Latin America (Brazil, Mexico and Argentina)

    5.2. Product Analysis- Packaging, Size, and Price

    5.3. Key Industry Development

    5.4. Pipeline Analysis

    5.5. Regulatory Scenario Assessment

    5.6. Overview of Total Surgical Procedures Requiring Postoperative Management

        5.6.1. U.S. Surgical Procedures Requiring Postoperative Pain Management

    5.7. COVID-19 Impact Analysis

6. Global Post-operative Pain Therapeutics Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. Opioids

        6.3.2. NSAIDs

        6.3.3. Local Anesthetics

        6.3.4. Tricyclic Antidepressants

        6.3.5. Antiepileptic Drugs

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Post-operative Pain Therapeutics Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2031

        7.3.1. Oral

        7.3.2. Intravenous

        7.3.3. Intramuscular

        7.3.4. Others

    7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Post-operative Pain Therapeutics Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

        8.3.4. Others

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Post-operative Pain Therapeutics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. U.S.

        9.2.2. European Union (EU5)

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Rest of the World (RoW)

    9.3. Market Attractiveness Analysis, by Region

10. U.S. Post-operative Pain Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2031

        10.2.1. Opioids

        10.2.2. NSAIDs

        10.2.3. Local Anesthetics

        10.2.4. Tricyclic Antidepressants

        10.2.5. Antiepileptic Drugs

        10.2.6. Others

    10.3. Market Value Forecast, by Route of Administration, 2017–2031

        10.3.1. Oral

        10.3.2. Intravenous

        10.3.3. Intramuscular

        10.3.4. Others

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

        10.4.4. Others

    10.5. Market Value Forecast, by Country, 2017–2031

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

11. European Union (EU5) Post-operative Pain Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. Opioids

        11.2.2. NSAIDs

        11.2.3. Local Anesthetics

        11.2.4. Tricyclic Antidepressants

        11.2.5. Antiepileptic Drugs

        11.2.6. Others

    11.3. Market Value Forecast, by Route of Administration, 2017–2031

        11.3.1. Oral

        11.3.2. Intravenous

        11.3.3. Intramuscular

        11.3.4. Others

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

        11.4.4. Others

    11.5. Market Value Forecast, by Country, 2017–2031

        11.5.1. Germany

        11.5.2. France

        11.5.3. U.K.

        11.5.4. Italy

        11.5.5. Spain

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country

12. Asia Pacific Post-operative Pain Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. Opioids

        12.2.2. NSAIDs

        12.2.3. Local Anesthetics

        12.2.4. Tricyclic Antidepressants

        12.2.5. Antiepileptic Drugs

        12.2.6. Others

    12.3. Market Value Forecast, by Route of Administration, 2017–2031

        12.3.1. Oral

        12.3.2. Intravenous

        12.3.3. Intramuscular

        12.3.4. Others

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

        12.4.4. Others

    12.5. Market Value Forecast, by Country, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. South Korea

        12.5.4. Singapore

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country

13. Latin America Post-operative Pain Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. Opioids

        13.2.2. NSAIDs

        13.2.3. Local Anesthetics

        13.2.4. Tricyclic Antidepressants

        13.2.5. Antiepileptic Drugs

        13.2.6. Others

    13.3. Market Value Forecast, by Route of Administration, 2017–2031

        13.3.1. Oral

        13.3.2. Intravenous

        13.3.3. Intramuscular

        13.3.4. Others

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

        13.4.4. Others

    13.5. Market Value Forecast, by Country, 2017–2031

        13.5.1. Brazil

        13.5.2. Argentina

        13.5.3. Chile

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country

14. Rest of the World (RoW) Post-operative Pain Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. Opioids

        14.2.2. NSAIDs

        14.2.3. Local Anesthetics

        14.2.4. Tricyclic Antidepressants

        14.2.5. Antiepileptic Drugs

        14.2.6. Others

    14.3. Market Value Forecast, by Route of Administration, 2017–2031

        14.3.1. Oral

        14.3.2. Intravenous

        14.3.3. Intramuscular

        14.3.4. Others

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

        14.4.4. Others

    14.5. Market Value Forecast, by Country, 2017–2031

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

15. Competition Landscape

    15.1. Competitive Business Strategies

    15.2. Company Profiles

        15.2.1. Mallinckrodt Pharmaceuticals

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Product Portfolio

            15.2.1.3. SWOT Analysis

            15.2.1.4. Strategic Overview

        15.2.2. Pfizer, Inc.

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Product Portfolio

            15.2.2.3. SWOT Analysis

            15.2.2.4. Strategic Overview

        15.2.3. Novartis AG

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Product Portfolio

            15.2.3.3. SWOT Analysis

            15.2.3.4. Strategic Overview

        15.2.4. Eli Lilly and Company

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Product Portfolio

            15.2.4.3. SWOT Analysis

            15.2.4.4. Strategic Overview

        15.2.5. Teva Pharmaceutical Industries Ltd.

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Product Portfolio

            15.2.5.3. SWOT Analysis

            15.2.5.4. Strategic Overview

        15.2.6. Camurus AB

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Product Portfolio

            15.2.6.3. SWOT Analysis

            15.2.6.4. Strategic Overview

        15.2.7. Bayer AG

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Product Portfolio

            15.2.7.3. SWOT Analysis

            15.2.7.4. Strategic Overview

        15.2.8. Pacira BioSciences, Inc.

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Product Portfolio

            15.2.8.3. SWOT Analysis

            15.2.8.4. Strategic Overview

        15.2.9. Trevena, Inc.

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Product Portfolio

            15.2.9.3. SWOT Analysis

            15.2.9.4. Strategic Overview

List of Tables

Table 01: Global Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 03: Global Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: U.S. Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 06: U.S. Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 07: U.S. Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 08: European Union (EU5) Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: European Union (EU5) Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 10: European Union (EU5) Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 11: European Union (EU5) Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: Asia Pacific Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 13: Asia Pacific Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 14: Asia Pacific Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 15: Asia Pacific Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Latin America Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 17: Latin America Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 18: Latin America Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 19: Latin America Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 20: Rest of the World Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 21: Rest of the World Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 22: Rest of the World Postoperative Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Post-operative Pain Therapeutics Market, by Drug Class, 2021 and 2031

Figure 02: Global Post-operative Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 03: Global Post-operative Pain Therapeutics Market (US$ Mn), by Opioids, 2017–2031

Figure 04: Global Post-operative Pain Therapeutics Market (US$ Mn), by NSAIDs, 2017–2031

Figure 05: Global Post-operative Pain Therapeutics Market (US$ Mn), by Local Anesthetics, 2017–2031

Figure 06: Global Post-operative Pain Therapeutics Market (US$ Mn), by Tricyclic Antidepressants, 2017–2031

Figure 07: Global Post-operative Pain Therapeutics Market (US$ Mn), by Antiepileptic Drugs, 2017–2031

Figure 08: Global Post-operative Pain Therapeutics Market (US$ Mn), by Others, 2017–2031

Figure 09: Global Post-operative Pain Therapeutics Market, by Route of Administration, 2021 and 2031

Figure 10: Global Post-operative Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 11: Global Post-operative Pain Therapeutics Market (US$ Mn), by Oral, 2017–2031

Figure 12: Global Post-operative Pain Therapeutics Market (US$ Mn), by Intravenous, 2017–2031

Figure 13: Global Post-operative Pain Therapeutics Market (US$ Mn), by Intramuscular, 2017–2031

Figure 14: Global Post-operative Pain Therapeutics Market (US$ Mn), by Others, 2017–2031

Figure 15: Global Post-operative Pain Therapeutics Market, by Distribution Channel, 2021 and 2031

Figure 16: Global Post-operative Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 17: Global Post-operative Pain Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2017–2031

Figure 18: Global Post-operative Pain Therapeutics Market (US$ Mn), by Retail Pharmacies, 2017–2031

Figure 19: Global Post-operative Pain Therapeutics Market (US$ Mn), by Online Pharmacies, 2017–2031

Figure 20: Global Post-operative Pain Therapeutics Market (US$ Mn), by Others, 2017–2031

Figure 21: Global Post-operative Pain Therapeutics Market, by Region, 2021 and 2031

Figure 22: Global Post-operative Pain Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

Figure 23: U.S. Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 24: U.S. Post-operative Pain Therapeutics Market, by Drug Class, 2021 and 2031

Figure 25: U.S. Post-operative Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 26: U.S. Post-operative Pain Therapeutics Market, by Route of Administration, 2021 and 2031

Figure 27: U.S. Post-operative Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 28: U.S. Post-operative Pain Therapeutics Market, by Distribution Channel, 2021 and 2031

Figure 29: U.S. Post-operative Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 30: European Union (EU5) Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 31: European Union (EU5) Post-operative Pain Therapeutics Market, by Country/Region, 2021 and 2031

Figure 32: European Union (EU5) Post-operative Pain Therapeutics Market Attractiveness Analysis, by Country/Region, 2022–2031

Figure 33: European Union (EU5) Post-operative Pain Therapeutics Market, by Drug Class, 2021 and 2031

Figure 34: European Union (EU5) Post-operative Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 35: European Union (EU5) Post-operative Pain Therapeutics Market, by Route of Administration, 2021 and 2031

Figure 36: European Union (EU5) Post-operative Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 37: European Union (EU5) Post-operative Pain Therapeutics Market, by Distribution Channel, 2021 and 2031

Figure 38: European Union (EU5) Post-operative Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 39: Asia Pacific Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 40: Asia Pacific Post-operative Pain Therapeutics Market, by Country, 2021 and 2031

Figure 41: Asia Pacific Post-operative Pain Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 42: Asia Pacific Post-operative Pain Therapeutics Market, by Drug Class, 2021 and 2031

Figure 43: Asia Pacific Post-operative Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 44: Asia Pacific Post-operative Pain Therapeutics Market, by Route of Administration, 2021 and 2031

Figure 45: Asia Pacific Post-operative Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 46: Asia Pacific Post-operative Pain Therapeutics Market, by Distribution Channel, 2021 and 2031

Figure 47: Asia Pacific Post-operative Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 48: Latin America Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 49: Latin America Post-operative Pain Therapeutics Market, by Country, 2021 and 2031

Figure 50: Latin America Post-operative Pain Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 51: Latin America Post-operative Pain Therapeutics Market, by Drug Class, 2021 and 2031

Figure 52: Latin America Post-operative Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 53: Latin America Post-operative Pain Therapeutics Market, by Route of Administration, 2021 and 2031

Figure 54: Latin America Post-operative Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 55: Latin America Post-operative Pain Therapeutics Market, by Distribution Channel, 2021 and 2031

Figure 56: Latin America Post-operative Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 57: Rest of the World Post-operative Pain Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

Figure 58: Rest of the World Post-operative Pain Therapeutics Market, by Drug Class, 2021 and 2031

Figure 59: Rest of the World Post-operative Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 60: Rest of the World Post-operative Pain Therapeutics Market, by Route of Administration, 2021 and 2031

Figure 61: Rest of the World Post-operative Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 62: Rest of the World Post-operative Pain Therapeutics Market, by Distribution Channel, 2021 and 2031

Figure 63: Rest of the World Post-operative Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

944

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved